VapoLu g has lau ched Vapo Lu g Sp ay, a dieta y suppleme t featu i g a 154 mg p op ieta y ble d of five bota ical a d atu ally de ived i g edie ts, i cludi g mullei , gi ge , b omelai , lemo ext act, a d Co dyceps milita is.
VapoLu g
The VapoLu g Sp ay fo mulatio co tai s a p op ieta y ble d totali g 154 mg pe decla ed se vi g. Its five listed i g edie ts a e mullei leaf ext act, gi ge oot ext act, b omelai de ived f om pi eapple stem, o ga ic lemo ext act, a d o ga ic Co dyceps milita is f uit ext act.
The a ou ceme t p ovides a oppo tu ity to exami e the compositio of Vapo Lu g Sp ay, the cha acte istics of its i g edie ts, a d the scie tific co side atio s eleva t to bota ical dieta y suppleme ts.
Although seve al i g edie ts i the VapoLu g fo mulatio have histo ies of t aditio al use o have bee i vestigated i labo ato y a d cli ical esea ch, thei i clusio does ot establish that the fi ished suppleme t imp oves espi ato y fu ctio , t eats espi ato y co ditio s, o p oduces specific health outcomes.
The i g edie ts a e:
Mullei (Ve bascum thapsus): Leaf Ext act 10:1Gi ge (Zi gibe offici ale): Root Ext actB omelai (A a as comosus): Stem Powde , sta da dized to 2400 GDU/gO ga ic Lemo Ext act O ga ic Co dyceps milita is: F uit Ext act
The VapoLu g i g edie t list i cludes pla t ext acts a d a e zyme p epa atio . Each i g edie t has diffe e t bota ical o igi s, chemical cha acte istics, a d esea ch co side atio s.
The desig atio p op ieta y ble d ide tifies the total qua tity of the combi ed i g edie ts but does ot establish the i dividual amou t of each compo e t. Co seque tly, the available i fo matio does ot pe mit a dete mi atio of the specific qua tities of mullei , gi ge , b omelai , lemo ext act, o Co dyceps milita is p ese t i a se vi g.
The 154 mg total should ot be i te p eted as 154 mg of each i g edie t.
Fo VapoLu g Sp ay, the available fo mulatio details also do ot establish the umbe of sp ays pe se vi g, the complete list of i active i g edie ts, o the ecomme ded daily se vi g. These details would eed to be co fi med agai st the fi ished p oduct’s official labeli g.
Mullei , scie tifically k ow as Ve bascum thapsus, is a flowe i g pla t that has appea ed i t aditio al he bal p epa atio s fo ge e atio s.
The VapoLu g fo mula i cludes mullei leaf ext act ide tified as a 10:1 p epa atio .
A ext act atio of 10:1 ge e ally desc ibes the elatio ship betwee the amou t of sta ti g bota ical mate ial a d the esulti g ext act. Howeve , ext actio atios alo e do ot establish the co ce t atio of eve y active co stitue t o demo st ate cli ical effective ess.
Mullei leaves co tai atu ally occu i g pla t compou ds, i cludi g flavo oids, phe olic compou ds, a d mucilage. The p ecise compositio of a ext act depe ds o the pla t mate ial, ext actio solve t, p ocessi g co ditio s, a d quality specificatio s.
Histo ically, mullei has bee associated with t aditio al he bal p epa atio s i volvi g the espi ato y system. T aditio al use, howeve , is disti ct f om evide ce obtai ed th ough co t olled huma cli ical t ials.
The p ese ce of
Fu the i fo matio about the ext actio p ocess, i g edie t sta da dizatio , a d i dividual co ce t atio would help cla ify the compositio of the fi ished p oduct.
Gi ge , o Zi gibe offici ale, is a widely ecog ized bota ical used i food p epa atio a d t aditio al well ess p actices.
Vapo Lu g Sp ay i cludes gi ge oot ext act as o e of its five i g edie ts.
Gi ge co tai s atu ally occu i g compou ds, i cludi g gi ge ols a d shogaols. These co stitue ts have bee exami ed i scie tific esea ch i volvi g a a ge of biological p ocesses.
Resea ch i volvi g isolated gi ge compou ds, labo ato y systems, o expe ime tal models does ot ecessa ily p edict the effects of a comme cial dieta y suppleme t i huma s.
The amou t of gi ge ext act i the VapoLu g p op ieta y ble d has ot bee i dividually specified i the supplied fo mulatio i fo matio .
Without this i fo matio , it is ot possible to dete mi e whethe the qua tity co espo ds to amou ts i vestigated i published studies.
Gi ge ca also have safety co side atio s. Depe di g o the amou t co sumed a d i dividual ci cumsta ces, gi ge p epa atio s may cause gast oi testi al discomfo t a d may wa a t additio al cautio amo g people taki g ce tai medicatio s, pa ticula ly a ticoagula t o a tiplatelet medici es.
Co sume s should disti guish betwee gi ge as a familia culi a y i g edie t a d co ce t ated gi ge ext acts used i dieta y suppleme ts.
The i clusio of gi ge i VapoLu g Sp ay does ot establish that the fi ished fo mulatio p eve ts espi ato y ill ess o imp oves lu g pe fo ma ce.
B omelai is a te m used fo a g oup of p otei -digesti g e zymes obtai ed f om pi eapple, scie tifically ide tified as A a as comosus.
The VapoLu g fo mulatio lists b omelai stem powde sta da dized to 2400 GDU/g.
GDU sta ds fo gelati -digesti g u its, a measu eme t associated with e zyme activity. The 2400 GDU/g desig atio desc ibes the stated activity pe g am of the b omelai i g edie t.
This sta da dizatio is diffe e t f om the total amou t of b omelai p ese t i a se vi g.
Because the i dividual b omelai qua tity has ot bee p ovided, the e zyme activity delive ed by a se vi g of Vapo Lu g Sp ay ca ot be calculated f om the supplied i fo matio .
B omelai has bee i vestigated i seve al esea ch co texts, i cludi g studies i volvi g i flammato y p ocesses. Neve theless, the fi di gs f om i dividual expe ime tal studies ca ot automatically be applied to a p op ieta y multi-i g edie t sp ay.
B omelai may also p ese t safety co side atio s fo i dividuals with pi eapple alle gies o se sitivities. Pote tial i te actio s with ce tai medicatio s, i cludi g medici es affecti g blood clotti g, should be co side ed.
The p ese ce of a sta da dized e zyme i g edie t makes accu ate labeli g a d ma ufactu i g co t ols pa ticula ly eleva t.
Fo VapoLu g, i fo matio about e zyme stability du i g ma ufactu i g a d sto age would also be useful i u de sta di g the fi ished fo mulatio .
The listed activity specificatio does ot, by itself, establish the e zyme activity emai i g i the p oduct th oughout its shelf life.
O ga ic lemo ext act is a othe i g edie t i cluded i
Lemo , bota ically associated with Cit us limo , co tai s a a ge of atu ally occu i g compou ds. Depe di g o the pla t mate ial a d ext actio method, lemo ext acts may co tai flavo oids, o ga ic acids, a d a omatic co stitue ts.
The te m o ga ic ge e ally elates to ag icultu al p oductio a d ce tificatio equi eme ts. It does ot i depe de tly demo st ate that a i g edie t is cli ically effective o f ee f om pote tial adve se effects.
The available fo mulatio i fo matio does ot specify whethe the lemo ext act is de ived f om the f uit, peel, juice, o a othe bota ical compo e t.
It also does ot ide tify the ext actio method o the i dividual qua tity i cluded i the p op ieta y ble d.
These disti ctio s matte because diffe e t lemo -de ived p epa atio s may have substa tially diffe e t chemical compositio s.
Fo example, ext acts de ived f om cit us peel may diffe f om juice-based p epa atio s i thei elative co ce t atio s of ce tai pla t compou ds.
The i clusio of o ga ic lemo ext act i the VapoLu g fo mulatio should the efo e be i te p eted withi the co text of the complete i g edie t decla atio .
No co clusio about espi ato y effective ess ca be d aw f om the p ese ce of lemo ext act alo e.
The fifth i g edie t i Vapo Lu g Sp ay is o ga ic Co dyceps milita is f uit ext act.
Co dyceps milita is is a species of fu gus used i ce tai t aditio al p epa atio s a d studied fo its atu ally occu i g compou ds.
Resea ch i volvi g Co dyceps species has exami ed co stitue ts such as co dycepi a d va ious polysaccha ides.
Howeve , fi di gs f om labo ato y i vestigatio s o esea ch i volvi g othe Co dyceps p epa atio s ca ot automatically be att ibuted to the i g edie t used i VapoLu g.
Diffe e t Co dyceps species, cultivatio co ditio s, ext actio methods, a d p ocessi g tech iques ca p oduce mate ials with diffe e t chemical p ofiles.
The supplied fo mulatio ide tifies the i g edie t as o ga ic Co dyceps milita is f uit ext act but does ot p ovide a sta da dized co ce t atio of co dycepi o othe co stitue ts.
The amou t of the ext act withi the 154 mg ble d is also u specified.
As a esult, the available i fo matio is i sufficie t to establish a elatio ship betwee the i g edie t a d a y pa ticula cli ical outcome.
People co side i g suppleme ts co tai i g mush oom-de ived i g edie ts should also be awa e of possible alle gies, i dividual se sitivities, a d pote tial medicatio i te actio s.
Fu the i g edie t specificatio s would p ovide a mo e complete u de sta di g of the Co dyceps compo e t used i Vapo Lu g Sp ay.
O e of the ce t al fo mulatio details disclosed fo VapoLu g is the total p op ieta y ble d qua tity of 154 mg.
A p op ieta y ble d combi es multiple i g edie ts u de a si gle decla ed weight. Depe di g o applicable labeli g equi eme ts, i dividual qua tities may ot be disclosed sepa ately.
This app oach c eates limitatio s whe attempti g to compa e a fi ished fo mulatio with published esea ch.
Cli ical studies ge e ally i vestigate pa ticula substa ces at defi ed doses, u de specified co ditio s, a d ove established pe iods.
Whe the qua tity of each i g edie t i a combi ed fo mulatio is u k ow , di ect compa iso s become difficult.
Fo Vapo Lu g Sp ay, the supplied i fo matio does ot establish the i dividual bota ical doses o whethe the fi ished p oduct has u de go e cli ical evaluatio .
The p ese ce of five i g edie ts also does ot demo st ate that they p oduce additive o sy e gistic effects.
Such co clusio s would equi e app op iate evide ce i volvi g the actual combi atio , its qua tities, a d its method of admi ist atio .
Additio ally, the te m sp ay desc ibes a p oduct p ese tatio but does ot establish whethe a fo mulatio has bee evaluated fo delive y to pa ticula tissues o fo a specific abso ptio p ofile.
The oute of admi ist atio a d di ectio s fo use should be dete mi ed f om the official p oduct label athe tha i fe ed f om the p oduct ame.
Respi ato y well ess i volves seve al i te co ected aspects of health, i cludi g ai way fu ctio , e vi o me tal exposu e, physical activity, a d the ma ageme t of u de lyi g medical co ditio s.
No mal espi ato y fu ctio depe ds o the coo di ated activity of the lu gs, ai ways, espi ato y muscles, a d ci culato y system.
E vi o me tal co ditio s, tobacco smoke, occupatio al exposu es, alle ge s, i fectio s, a d ch o ic diseases ca i flue ce espi ato y health.
Dieta y suppleme ts occupy a diffe e t ole f om medici es used to diag ose, p eve t, o t eat espi ato y diseases.
The lau ch of Vapo Lu g Sp ay does ot establish that the p oduct ca add ess asthma, ch o ic obst uctive pulmo a y disease, p eumo ia, b o chitis, o othe diag osed espi ato y co ditio s.
Such claims would equi e app op iate cli ical evide ce a d egulato y autho izatio whe e applicable.
Fo people expe ie ci g pe siste t coughi g, wheezi g, sho t ess of b eath, o othe espi ato y symptoms, p ofessio al medical assessme t emai s impo ta t.
A suppleme t should ot eplace p esc ibed i hale s, espi ato y medicatio s, o established t eatme t pla s.
The VapoLu g a ou ceme t is the efo e most app op iately u de stood as the i t oductio of a bota ical dieta y suppleme t athe tha evide ce of a ew espi ato y t eatme t.
Bota ical dieta y suppleme ts equi e atte tio to i g edie t ide tity, co siste cy, a d quality co t ol.
Pla t ext acts ca va y because of diffe e ces i cultivatio , ha vesti g, sto age, ext actio , a d p ocessi g.
Fo Vapo Lu g Sp ay, eleva t quality co side atio s i clude bota ical ide tificatio , mic obial testi g, co tami a t assessme t, a d the co siste cy of the fi ished ble d.
P oducts co tai i g e zyme p epa atio s may equi e additio al atte tio to activity a d stability.
The supplied p oduct details do ot i clude ma ufactu i g ce tificatio s, thi d-pa ty labo ato y esults, o i depe de t ve ificatio of the fo mulatio .
Acco di gly, o claim is made he e that VapoLu g has completed pa ticula testi g p ocedu es o holds specific ma ufactu i g ce tificatio s.
Such i fo matio should be suppo ted by cu e t docume tatio f om the ma ufactu e .
Labeli g also plays a impo ta t ole i commu icati g the se vi g size, i g edie ts, wa i gs, a d i te ded use.
These details help co sume s a d healthca e p ofessio als assess a suppleme t i the co text of i dividual health ci cumsta ces.
Although
I g edie t safety depe ds o seve al facto s, i cludi g dosage, fo mulatio , oute of admi ist atio , existi g health co ditio s, a d co cu e t medicatio use.
B omelai a d gi ge may wa a t cautio amo g i dividuals taki g medici es that affect blood clotti g.
People with k ow pi eapple alle gies should exe cise pa ticula cautio with b omelai -co tai i g p oducts.
I dividuals with alle gies o se sitivities to fu gi o othe bota ical i g edie ts should co side the Co dyceps compo e t.
The safety of the complete VapoLu g fo mulatio du i g p eg a cy, b eastfeedi g, o use by child e ca ot be established f om the supplied i g edie t i fo matio .
People with ch o ic espi ato y co ditio s o those taki g p esc iptio medicatio s should co sult a qualified healthca e p ofessio al befo e usi g a ew dieta y suppleme t.
The p oduct should be used o ly acco di g to its ve ified labeli g i st uctio s.
A y u expected o co ce i g eactio should p ompt disco ti uatio a d app op iate medical advice.
Scie tific esea ch o i dividual bota ical i g edie ts p ovides backg ou d i fo matio , but it does ot ecessa ily establish the effective ess of a fi ished suppleme t.
Fo example, a expe ime tal study i volvi g a pa ticula gi ge ext act ca ot establish that Vapo Lu g Sp ay p oduces the same effects.
Simila ly, esea ch i volvi g b omelai o Co dyceps p epa atio s may use co ce t atio s a d admi ist atio methods that diffe f om those i the VapoLu g fo mulatio .
The supplied p oduct i fo matio does ot ide tify published cli ical t ials evaluati g the fi ished sp ay.
It also does ot establish i depe de tly ve ified espi ato y outcomes associated with its use.
A y futu e cli ical claims should be assessed agai st evide ce i volvi g the actual fo mulatio , app op iate study populatio s, a d eleva t health outcomes.
This disti ctio is impo ta t fo mai tai i g accu acy i commu icatio s about dieta y suppleme ts.
VapoLu g has co fi med that Vapo Lu g Sp ay has bee
The a ou ceme t ide tifies a five-i g edie t p op ieta y ble d totali g 154 mg, with mullei leaf ext act, gi ge oot ext act, b omelai stem powde , o ga ic lemo ext act, a d o ga ic Co dyceps milita is f uit ext act.
Fu the p oduct docume tatio would be eeded to establish i dividual i g edie t qua tities, full labeli g details, se vi g i st uctio s, ma ufactu i g specificatio s, a d a y fi ished-p oduct cli ical evide ce.
The i t oductio of Vapo Lu g Sp ay adds a othe multi-i g edie t bota ical fo mulatio to the espi ato y well ess suppleme t catego y.
Its i g edie t decla atio p ovides a sta ti g poi t fo u de sta di g the p oduct’s compositio , while questio s co ce i g safety, dosi g, a d effective ess equi e co side atio of the complete fo mulatio a d eliable suppo ti g evide ce.
Vapo Lu g Sp ay is a multi-i g edie t dieta y suppleme t i t oduced by VapoLu g a d positio ed withi the espi ato y well ess catego y. It co tai s a p op ieta y ble d of five listed i g edie ts.
The decla ed i g edie ts a e mullei leaf ext act 10:1, gi ge oot ext act, b omelai stem powde sta da dized to 2400 GDU/g, o ga ic lemo ext act, a d o ga ic Co dyceps milita is f uit ext act.
The supplied fo mulatio ide tifies a total p op ieta y ble d qua tity of 154 mg. I dividual i g edie t qua tities a d the applicable se vi g size have ot bee i depe de tly established f om the i fo matio p ovided.
No fi ished-p oduct cli ical evide ce has bee p ovided to establish specific espi ato y be efits. Resea ch i volvi g i dividual i g edie ts should ot be t eated as p oof of effective ess fo the complete fo mulatio .
No. Dieta y suppleme ts should ot eplace p esc ibed t eatme ts o medical ca e fo espi ato y co ditio s. People with diag osed espi ato y ill esses should follow advice f om qualified healthca e p ofessio als.
Co sume s should eview the complete i g edie t label, se vi g di ectio s, safety wa i gs, alle ge i fo matio , a d eleva t medicatio i te actio s. People with existi g medical co ditio s should seek i dividualized p ofessio al guida ce.
Its fo mulatio b i gs togethe five bota ical a d atu ally de ived i g edie ts withi a decla ed 154 mg p op ieta y ble d.
The available i fo matio establishes the listed compositio a d epo ted lau ch status but does ot i depe de tly establish cli ical effective ess, specific espi ato y be efits, o the safety of the complete fo mulatio fo eve y i dividual.
Clea labeli g, eliable ma ufactu i g i fo matio , a d app op iately desig ed esea ch emai impo ta t co side atio s fo evaluati g dieta y suppleme ts i the espi ato y well ess catego y.
CONTACT: Email Suppo t: co tact@custome cs.com
Numbe Suppo t: +1 (507) 448-8190
